logo-loader
viewIntegumen

Integumen posts 1,200% rise in first-half revenue as big cosmetics companies sign up to use Labskin

Labskin is a lab-grown skin which cosmetic companies can use to test their latest products in a real-world setting

skin cream
Contract sizes have increased from £1,500 last year, to upwards of £200,000 this year

Integumen PLC’s (LON:SKIN) revenues soared by over 1,000% in the first half of the year as blue-chip customers continue to sign up for its cosmetics testing services.

Revenues jumped to £655,000 in the six months to the end of June, compared with just £54,000 a year earlier.

READ: Integumen sees revenues double in 'transformational' year

Since taking over a year ago, chief executive Gerry Brandon has adapted and improved Integumen’s flagship product, Labskin – a lab-grown skin which cosmetic companies can use to test their latest products in a real-world setting.

Rather than selling one-off skin-testing kits, Integumen now offers a fully-fledged testing platform. As a result, it can now charge significantly more for customers to use its services.

Last year, a customer would sign contracts worth as little as £1,500, but now, Integumen is commanding upwards of £30,000. In one case, it struck a deal worth £210,000.

Among the new clients are a couple of “blue-chip household names”, Integumen said.

Boss has been busy

“We are delighted to see that the major changes made to our strategy are bearing fruit already,” said CEO Brandon.

“In addition to a growing customer base and accelerated high-margin sales, we have taken steps to reduce company indebtedness by eliminating more than £2mln short- and long-term debt, disposing of multiple under-performing assets and completed placing, subscription and warrant exercises that have brought in in excess of £3mln in H1 2019.

“The board expects that we will continue to see this strong growth in the second half of the year, and we view the future with confidence.”

Shares were up 1% to 1.99p in early deals on Monday.

--Adds share price and amends headline--

Quick facts: Integumen

Price: 1.875 GBX

AIM:SKIN
Market: AIM
Market Cap: £18.4 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Integumen named herein, including the promotion by the Company of Integumen in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: SkinBio signs commercial deal with chemical giant Croda

Headlines from the Proactive UK newsroom. SkinBioTherapeutics (LON:SBTX) has signed a commercial and manufacturing agreement for its Skinbiotix technology with speciality chemical giant Croda.  It is the first major deal for the product with Croda to design and manufacture a new active...

11 hours, 51 minutes ago

2 min read